Development of NSAIDs with lower gastric side effect
Development of NSAIDs with lower gastric side effect
复制标题
开发具有较低胃副作用的非甾体抗炎药
DOI:
10.1159/000338396
复制
发表时间:
2012
期刊:
影响因子:
--
通讯作者:
T
中科院分区:
文献类型:
--
作者:
Mizushima;T
NSAIDs are one of the most frequently used classes of medicines in the world and account for nearly 5% of all prescribed medications1). However, NSAID administration is associated with gastrointestinal complications, such as gastric ulcers and bleeding, which sometimes become life-threatening diseases2). About 15-30% of chronic users of NSAIDs have gastrointestinal ulcers and bleeding. In the United States, about 16,500 people per year die as a result of NSAID-associated gastrointestinal complications3). Therefore, the molecular mechanism governing NSAID-induced gastrointestinal damage needs to be elucidated in order to develop new NSAIDs that do not have these side effects. Inhibition of COX by NSAIDs, which is responsible for their anti-inflammatory activity was previously thought to be fully responsible for their gastrointestinal side effects4). There are at least two subtypes of COX, COX-1 and COX-2, which are responsible for the majority of COX activity at the gastric mucosa and tissues with inflammation, respectively. Therefore, it is reasonable to speculate that selective COX-2 inhibitors have antiinflammatory activity without gastrointestinal side effects. In fact,
登录
查看更多内容
影响因子:
12.4
作者:
Tsutsumi, S;Gotoh, T;Mizushima, T
通讯作者:
Mizushima, T
影响因子:
16
作者:
Yu, J;Zhang, L;Vogelstein, B
通讯作者:
Vogelstein, B
DOI:
10.1016/j.bbrc.2007.03.034
发表时间:
2007-05-11
影响因子:
3.1
作者:
Ishihara, Tomoaki;Hoshino, Tatsuya;Mizushima, Tohru
通讯作者:
Mizushima, Tohru
影响因子:
4.1
作者:
S. Kawano;Shingo Tsuji;N. Hayashi;Y. Takei;K. Nagano;H. Fusamoto;T. Kamada
通讯作者:
T. Kamada